Shares of Compass Pathways Plc (NASDAQ:CMPS) rose about 3% in premarket trading on Wednesday after the company said the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND ...

The field of psychedelic medicine is relatively new, and because of this, certain investors consider it to be loaded with potential. That's why even minor events in companies specializing in this can ...

Compass Pathways (NASDAQ:CMPS) shares rose nearly 9% premarket on Friday after the biotechnology company priced a securities offering to raise up to $353M. The company is offering ~24.01M American ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, COMPASS ...

COMPASS Pathways PLC Sponsored ADR (CMPS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

Compass Pathways plc (NASDAQ:CMPS) released data from the Phase 3 COMP005 trial, the first of two Phase 3 trials evaluating COMP360 for treatment-resistant depression (TRD). Despite meeting the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Analyst expectations are far above the prices you'd need to pay now to own a couple of biotechnology stocks. Compass Pathways is developing psilocybin as a treatment for depression. Viking ...

Franklin Resources Inc. boosted its stake in shares of COMPASS Pathways plc (NASDAQ:CMPS – Free Report) by 4.4% during the 3rd quarter, according to the company in its most recent filing with the ...